Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti–β<sub>2</sub>‐Glycoprotein I and Small Dense High‐Density Lipoprotein Particles

Parra, Sandra; López‐Dupla, Miguel; Ibarretxe, Daiana; Heras, Mercedes; Amigó, Núria; Català, Alba; Benavent, M. Oltra; Garcés, Esperanza; Navarro, Álvaro Castillo; Castro, Antoni

doi:10.1002/acr.23594

Cited by 14 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rheological studies demonstrated how SLE patients present higher blood viscosity and RBC deformability, and aggregation rates, correlating with disease severity and cardiovascular complications 95,98,273 . Arterial stiffness in SLE patients was found to be affected, as reported in a number of clinical studies for different drugs and disease severity diagnoses 274–277 …”

Section: Autoimmune Diseasesmentioning

confidence: 75%

See 1 more Smart Citation

Advances in mechanical biomarkers

Eroles

Rico

2023

J of Molecular Recognition

View full text Add to dashboard Cite

Mechanical biomarkers distinguish health conditions through quantitative mechanical measurements. The emergence and establishment of nanotechnology in the last decades have provided new tools to obtain mechanical biomarkers at the nanoscale.Mechanical measurements are reproducible, label-free, start to be applied in vivo can be high throughput, and require small samples. Mechanical protocols in clinical practice at the macro scale like palpation or blood pressure measurement are routinely used by medical doctors. Nanotechnology brought mechanical sensing to the next scale, where cells, tissues, and proteins can be probed and linked to medical conditions. Mechanical changes in cells and tissues may be detected before other markers, such as protein expression, providing an important advantage as biomarkers. In the present review, we explore the biomarker's historical evolution, describe mechanical biomarkers on various diseases and novel discoveries in the nanomechanical field for their characterization. We conclude that mechanical biomarkers are establishing novel hallmarks in diseases, in several cases for early diagnostics of diseases and discovery of drug targets in the proteins involved in the mechanical changes, while advances in instrumentation are bringing commercial products into the clinical practice. Mechanical biomarkers along with clinical testing are establishing an important niche in the market, whose demand is increasing due to the expansion of personalized medicine and unmet needs in the clinics.

show abstract

Section: Autoimmune Diseasesmentioning

confidence: 75%

“…95,98,273 Arterial stiffness in SLE patients was found to be affected, as reported in a number of clinical studies for different drugs and disease severity diagnoses. [274][275][276][277] Inflammatory rheumatic diseases are a group of ADs affecting the motor and joint systems. 278 Rheumatoid arthritis has been associated…”

Section: Autoimmune Diseasesmentioning

confidence: 99%

Advances in mechanical biomarkers

Eroles

Rico

2023

J of Molecular Recognition

View full text Add to dashboard Cite

show abstract

“…Among disease-related features, we found an association between cfPWV and anti-β2GPI IgM positivity. Interestingly, Parra et al [ 39 ] have also shown a significant association between AIx levels and positive anti-β2GPI IgM in SLE patients ( p = 0.035). We also demonstrated that cfPWV was independently associated with femoral artery atherosclerosis.…”

Section: Discussionmentioning

confidence: 96%

Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome

et al. 2023

View full text Add to dashboard Cite

Objectives Cardiovascular disease is a major cause of morbidity and mortality in antiphospholipid syndrome (APS). Arterial stiffness (ArS) has emerged as predictor of future cardiovascular events in the general population. We aimed to assess ArS in patients with thrombotic APS versus diabetes mellitus (DM) and healthy controls (HC), and identify predictors of increased ArS in APS. Methods ArS was evaluated by carotid-femoral Pulse Wave Velocity (cfPWV) and Augmentation Index normalized to 75 beats/min (AIx@75), using the SphygmoCor device. Participants also underwent carotid/femoral ultrasound for atherosclerotic plaques detection. We used linear regression to compare ArS measures among groups and assess ArS determinants in APS group. Results We included 110 patients with APS (70.9% female, mean age: 45.4 years), 110 DM patients and 110 HC, all age/sex matched. After adjustment for age, sex, cardiovascular risk factors and plaque presence, APS patients exhibited similar cfPWV (beta=-0.142, 95% CI: -0.514–0.230, p= 0.454) but increased AIx@75 (beta = 4.525, 1.372–7.677, p= 0.005) compared with HC, and lower cfPWV (p< 0.001) but similar AIx@75 (p= 0.193) vs DM patients. In APS group, cfPWV was independently associated with age (beta = 0.056, 0.034–0.078, p< 0.001), mean arterial pressure (MAP) (beta = 0.070, 0.043–0.097, p< 0.001), atherosclerotic femoral plaques (beta = 0.732, 0.053–1.411, p= 0.035) and anti-β2GPI IgM positivity (beta = 0.696, 0.201–1.191, p= 0.006). AIx@75 was associated with age (beta = 0.334, 0.117–0.551, p= 0.003), female sex (beta = 7.447, 2.312–12.581, p= 0.005) and MAP (beta = 0.425, 0.187–0.663, p= 0.001). Conclusion APS patients exhibit elevated AIx@75 versus HC, and similar to DM, indicating enhanced arterial stiffening in APS. Given its prognostic value, ArS evaluation may help to improve cardiovascular risk stratification in APS.

show abstract

“…Cyclophosphamide, a clinically potent immunosuppressant, acts as an antiinflammatory agent by effectively blocking the release of cytokines. Immunoglobulin index refers to immune protein components extracted from healthy plasma and purified and formulated through a series of processes [16]. The use of prednisone in combination with immunesuppressive therapy for SLE patients boosts immunity thereby improving the patient's conditions.…”

Section: Discussionmentioning

confidence: 99%

Effect of combined use of prednisone and immunosuppressive therapy in patients with systemic lupus erythematosus, and its influence on incidence of adverse reactions

Liu¹,

Wang²,

Wang³

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To study the effect of combined use of prednisone and immunosuppressive therapy for systemic lupus erythematosus (SLE), and its impact on the incidence of adverse reactions.Methods: In total, 90 SLE patients treated in Longhui People's Hospital between January 2019 and January 2020 were included in this study, and assigned to receive either prednisone (control group) or immunosuppressive therapy and prednisone (study group) via the sealed envelope method. Outcome measures include immunoglobulin measured by enzyme-linked immunosorbent assay (ELISA), complement component 3 (C3) and C4 determined by immunoturbidimetric method, inflammatory factors such as INF-α, IL-10, and IL-6 levels, and the incidence of drug reactions.Results: After treatment, the treatment group had higher levels of immunoglobulin indices and C3 and C4 levels than the control group (p < 0.05). There were lower serum inflammatory factor levels in the treatment group than in the control group (p < 0.05). Prednisone and immunosuppressive therapy resulted in higher treatment effectiveness and lower SLEDAI scores, versus prednisone alone (p < 0.05).Conclusion: Prednisone and immunosuppressive therapy for SLE is safe, enhances treatment effectiveness, and improves clinical indicators in the patients. However, further trials are required prior to its application in clinical practice.

show abstract

Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti–β₂‐Glycoprotein I and Small Dense High‐Density Lipoprotein Particles

Cited by 14 publications

References 49 publications

Advances in mechanical biomarkers

Advances in mechanical biomarkers

Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome

Effect of combined use of prednisone and immunosuppressive therapy in patients with systemic lupus erythematosus, and its influence on incidence of adverse reactions

Contact Info

Product

Resources

About

Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti–β2‐Glycoprotein I and Small Dense High‐Density Lipoprotein Particles

Cited by 14 publications

References 49 publications

Advances in mechanical biomarkers

Advances in mechanical biomarkers

Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome

Effect of combined use of prednisone and immunosuppressive therapy in patients with systemic lupus erythematosus, and its influence on incidence of adverse reactions

Contact Info

Product

Resources

About

Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti–β₂‐Glycoprotein I and Small Dense High‐Density Lipoprotein Particles